Intech Biopharm Corporation (TPEX: 6461)

Market Cap	4.05B
Revenue (ttm)	32.28M
Net Income (ttm)	-351.58M
Shares Out	137.41M
EPS (ttm)	-2.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	215,209
Open	29.95
Previous Close	29.50
Day's Range	29.80 - 30.90
52-Week Range	23.60 - 34.60
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 82
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6461

Financial Performance

In 2023, Intech Biopharm's revenue was 25.85 million, an increase of 9.30% compared to the previous year's 23.65 million. Losses were -337.99 million, 3.08% more than in 2022.